PubMed Health treatment related to Food Allergy: 62
The main thing people can do to prevent allergic reactions is avoid the food that causes them. Medication is generally only used in acute situations, if people have a more severe allergic reaction . It doesn’t tend to be used for the long-term treatment of food allergies . Anaphylactic reactions are treated using emergency kits. These contain medications to reduce severe allergic reactions and prevent them from getting worse.
Drugs for Food Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 215)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Montelukast |
Approved |
Phase 4 |
|
158966-92-8 |
5281040 |
Synonyms:
(R-(e))-1-(((1-(3-(2-(7-chloro-2-Quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetate
(R-(e))-1-(((1-(3-(2-(7-chloro-2-Quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
{1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetate
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulphanyl]methyl]cyclopropaneacetate
1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-Quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulphanyl]methyl]cyclopropaneacetic acid
151767-02-1 (sodium)
158966-92-8
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
AC1NQXXW
Apxi toxin
BIDD:GT0394
Brondilat
Brondilat (TN)
C07482
C35H36ClNO3S
Cahill may roberts brand OF montelukast sodium
CHEBI:50730
CHEMBL787
CID5281040
|
D08229
DB00471
HMS2089D07
HSDB 7582
LS-173539
Merck brand OF montelukast sodium
Merck frosst brand OF montelukast sodium
Merck sharp and dohme brand OF montelukast sodium
MK 0476
MK-0476
Montair
montelukast
Montelukast
Montélukast
Montelukast (INN)
Montelukast [INN:BAN]
Montelukast sodium
Montelukastum
Singulair
Singular
sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
UNII-MHM278SD3E
|
|
2 |
|
Omeprazole |
Approved, Investigational, Vet_approved |
Phase 4 |
|
73590-58-6 |
4594 |
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(S)-(-)-Omeprazole
(S)-Omeprazole
119141-89-8
131959-78-9
172964-80-6
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
2,3,5-Trimethylpyridine/Omeprazole
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
73590-58-6
AC1L1IIJ
AC-401
AGI-010
AKOS005066653
Antra
Antra mups
Antra MUPS
Audazol
Aulcer
AULCER
Axagon
Belmazol
BIDD:GT0189
Bio-0888
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
C07324
CAS-73590-58-6
CCRIS 7099
Ceprandal
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CPD000058847
D00455
Danlox
DB00338
DB00736
Demeprazol
Desec
Dizprazol
DM-3458
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
esomeprazol
Esomeprazole
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168-68
H168/68
H-168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
Indurgan
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
LS-7629
Lucen
Magnesium, omeprazole
Maybridge4_002645
Mepral
Miol
Miracid
MLS000069373
MLS001076112
MLS001424148
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
Mopral
Morecon
NCGC00016925-01
NCGC00016925-02
|
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
omeprazole
Omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazole pellets
Omeprazole sodium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
OMP
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Prazentol
Prazidec
Prazolit
Prestwick_808
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prilosec
Prilosec (TN)
Prilosec otc
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
Sanamidol
Secrepina
SMR000058847
Sodium, omeprazole
SPBio_002306
STK623746
Tedec ulceral
Tedec Ulceral
TL8005099
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
UNII-KG60484QX9
UPCMLD-DP075
UPCMLD-DP075:001
Victrix
Zefxon
Zegerid
Zepral
Zimor
Zoltum
|
|
3 |
|
Mannitol |
Approved, Investigational |
Phase 4 |
|
69-65-8 |
6251 453 |
Synonyms:
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
Ambap69-65-8
AR-1J3861
bmse000099
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
cpd without stereochemical designation
D-(-)-Mannitol
D00062
D008353
Diosmol
DL-Mannitol
D-mannite
D-mannitol
D-Mannitol
D-Mannitol (JP15)
Dulcite
e 421
e421
e-421
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Hexahydroxyhexane
Hexanhexol
HSDB 714
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
|
M9546_SIAL
M9647_SIAL
Manicol
manita
Manitol
Maniton S
Maniton-S
Manna sugar
Manna Sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit P
Mannite
mannitol
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol [USAN]
Mannitol 10%
Mannitol 10% In Plastic Container
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Mannitol 15%
Mannitol 15% In Plastic Container
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
Mannitol 20%
Mannitol 20% In Plastic Container
MANNITOL 25%
Mannitol 5%
Mannitol 5% In Plastic Container
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
Mannitolum
Mannogem 2080
Marine crystal
Marine Crystal
MLS001335977
MLS001335978
MolPort-003-927-039
MTL
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
Osmitrol 15% In Water
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Osmitrol 20% In Water
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Osmitrol 5% In Water
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM no. 35
SDM No. 35
SMR000857324
Sorbitol-Mannitol
SORBITOL-MANNITOL IN PLASTIC CONTAINER
TL806434
UNII-3OWL53L36A
ZINC02041302
|
|
4 |
|
Fluticasone |
Approved, Experimental |
Phase 4 |
|
90566-53-3 |
62924 |
Synonyms:
90566-53-3
AC1NSJZT
AC-456
BIDD:GT0819
C07815
CHEMBL1201396
CID5311101
D07981
Fluticaps
|
Fluticaps (TN)
Fluticason
Fluticasona
fluticasone
Fluticasone
Fluticasone (INN)
Fluticasonum
MolPort-006-666-449
S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
|
|
5 |
|
Omalizumab |
Approved, Investigational |
Phase 4 |
|
242138-07-4 |
|
Synonyms:
242138-07-4
D05251
Omalizumab
Omalizumab (genetical recombination)
|
Omalizumab (genetical recombination) (JAN)
Omalizumab (USAN/INN)
Xolair
Xolair (TN)
|
|
6 |
|
BCG vaccine |
Investigational |
Phase 4 |
|
|
|
Synonyms:
Bacillus calmette-guerin live antigen, unspecified substrain
|
|
|
7 |
|
Mesalamine |
|
Phase 4 |
|
89-57-6 |
|
8 |
|
Calcium Supplement |
|
Phase 4 |
|
|
|
9 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
10 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
11 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
12 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
13 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
14 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
15 |
|
Mydriatics |
|
Phase 4 |
|
|
|
16 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
17 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
18 |
|
Hormones |
|
Phase 4 |
|
|
|
19 |
|
Leukotriene Antagonists |
|
Phase 4 |
|
|
|
20 |
|
Antacids |
|
Phase 4 |
|
|
|
21 |
|
Anti-Ulcer Agents |
|
Phase 4 |
|
|
|
22 |
|
diuretics |
|
Phase 4 |
|
|
|
23 |
|
Vaccines |
|
Phase 4 |
|
|
|
24 |
|
Adjuvants, Immunologic |
|
Phase 4 |
|
|
|
25 |
|
Adrenocorticotropic Hormone |
|
Phase 4 |
|
|
|
26 |
|
Corticotropin-Releasing Hormone |
|
Phase 4 |
|
|
|
27 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
28 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
29 |
|
Azithromycin |
Approved |
Phase 3 |
|
83905-01-5 |
447043 55185 |
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside
121470-24-4
1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-,(2R-(2R*,3S*
75199_FLUKA
83905-01-5
9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A
AC-16014
AC1L9KEG
Aritromicina
Azadose
Azasite
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
azithromycin
Azithromycin
Azithromycin & Tumor Necrosis Factor
Azithromycin (AIDS Initiative)
Azithromycin (anhydrous)
Azithromycin dihydrate
Azithromycin monohydrate
Azithromycin Monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromax
Azitromicina
Azitromin
Azythromycin
Bayer brand OF azithromycin dihydrate
BIDD:GT0792
Bio-0676
BRN 5387583
BSPBio_002285
C38H72N2O12
CCRIS 1961
CHEBI:2955
CHEMBL529
CID447043
CP62,993
CP-62993
CPD000471864
DCH3
Dihydrate, azithromycin
DivK1c_000233
DRG-0104
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
HMS1922G12
|
HMS2094M11
HMS500L15
HSDB 7205
IDI1_000233
KBio1_000233
KBio2_000787
KBio2_003355
KBio2_005923
KBio3_001505
KBioGR_000731
KBioSS_000787
Lesvi brand OF azithromycin dihydrate
LS-1834
Mack brand OF azithromycin dihydrate
Misultina
MLS001055353
MLS001066331
MLS001201763
MLS001304005
MLS001332499
MLS001332500
MolPort-002-507-426
Monohydrate, azithromycin
NCGC00090753-01
NCGC00090753-02
NINDS_000233
NSC643732
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
SAM002589961
SMR000471864
SPBio_001544
Spectrum_000307
SPECTRUM1503679
Spectrum2_001582
Spectrum3_000653
Spectrum4_000186
Spectrum5_001867
Sumamed
Toraseptol
Tromix
Ultreon
UNII-JTE4MNN1MD
Vinzam
Vita brand OF azithromycin dihydrate
XZ-450
Zentavion
ZIT
Zithromac
Zithromax
Zithromax IV
Zithromycin
Zitromax
Zitromax Avium 600
Zmas
Zmax
Z-Pak
|
|
30 |
|
Zinc |
Approved, Investigational |
Phase 3 |
|
7440-66-6 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
31 |
|
Hydroxychloroquine |
Approved |
Phase 3 |
|
118-42-3 |
3652 |
Synonyms:
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
118-42-3
2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
5-22-10-00280 (Beilstein Handbook Reference)
747-36-4 (sulfate (1:1) salt)
7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline
7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
AC1L1GEW
Axemal
BRN 0253894
C07043
C18H26ClN3O
CHEMBL1535
CID3652
D08050
DB01611
DivK1c_000942
Dolquine
EINECS 204-249-8
Ercoquin
Gen-Hydroxychloroquine 200mg Tablets
HCQ
|
Hidroxicloroquina
Hidroxicloroquina [inn-spanish]
Hidroxicloroquina [INN-Spanish]
HMS502P04
Hydroxychlorochin
Hydroxychloroguine
hydroxychloroquine
Hydroxychloroquine
Hydroxychloroquine (INN)
Hydroxychloroquine [INN:BAN]
Hydroxychloroquine sulfate
Hydroxychloroquine sulfate (1:1) salt
Hydroxychloroquine Sulfate (1:1) Salt
Hydroxychloroquinum
Hydroxychloroquinum [inn-latin]
Hydroxychloroquinum [INN-Latin]
IDI1_000942
Idrossiclorochina
Idrossiclorochina [dcit]
Idrossiclorochina [DCIT]
KBio1_000942
LS-66614
MolPort-003-847-792
NCGC00159483-02
NINDS_000942
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
PlaqueN/A
Plaquenil
Polirreumin
Polirreumin (TN)
Quensyl
SPBio_001116
Spectrum2_001238
Spectrum5_001697
ST072188
UNII-4QWG6N8QKH
WIN 1258
|
|
32 |
|
Glutamic acid |
Approved, Nutraceutical |
Phase 3 |
|
56-86-0 |
33032 |
Synonyms:
(2S)-2-Aminopentanedioate
(2S)-2-Aminopentanedioic acid
(S)-(+)-Glutamate
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioate
(S)-2-Aminopentanedioic acid
(S)-Glutamate
(S)-Glutamic acid
09581_FLUKA
10549-13-0
138-15-8 (unspecified hydrochloride)
138-16-9
16690-92-9 (di-hydrochloride salt)
19238-49-4 (unspecified calcium salt)
19473-49-5 (mono-potassium salt)
1-amino-Propane-1,3-dicarboxylate
1-Aminopropane-1,3-dicarboxylate
1-amino-Propane-1,3-dicarboxylic acid
1-Aminopropane-1,3-dicarboxylic acid
1ftj
1ii5
1xff
24595-14-0 (unspecified potassium salt)
24938-00-9
25513-46-6
26717-13-5
27322E29-9696-49C1-B541-86BEF72DE2F3
2-Aminoglutarate
2-Aminoglutaric acid
2-Aminopentanedioate
2-aminopentanedioic acid
2-Aminopentanedioic acid
49449_FLUKA
49449_SIGMA
55695-80-2 (mono-lithium salt)
56-86-0
6899-05-4
7558-63-6 (mono-ammonium salt)
84960-48-5
a-Aminoglutarate
a-Aminoglutaric acid
AB1002631
AC-11294
AC1L1OVN
AC1Q28OF
AC1Q4U8B
AC1Q4U8C
Acide glutamique
Acide glutamique [INN-French]
acido Glutamico
Acido glutamico
ácido glutámico
Acido glutamico [INN-Spanish]
Acidum glutamicum
Acidum glutamicum [INN-Latin]
Acidum glutaminicum
Aciglut
a-Glutamate
a-Glutamic acid
AI3-18472
alpha-Aminoglutarate
alpha-aminoglutaric acid
alpha-Aminoglutaric acid
alpha-Aminoglutaric acid (VAN)
alpha-Glutamate
alpha-Glutamic acid
alpha-L-Glutamic acid polymer
Aluminum L glutamate
Aluminum L-glutamate
AmbotzHAA1087
Aminoglutarate
Aminoglutaric acid
Biomol-NT_000170
BPBio1_001132
C00025
CCRIS 7314
CHEBI:16015
CHEMBL575060
CID33032
D Glutamate
D00007
DB00142
DB02517
D-Glutamate
D-Glutamiensuur
E
E 620
EINECS 200-293-7
EPA Pesticide Chemical Code 374350
FEMA No. 3285
|
FT-0085107
G0059
G1251_SIGMA
G5667_SIGMA
G8415_SIGMA
Glt
glu
Glu
Glusate
glut
Glut
glutacid
Glutacid
glutamate
Glutamate
Glutamate, potassium
Glutamic acid
GLUTAMIC ACID
Glutamic acid (H-3)
Glutamic Acid (L-glutamic acid)
Glutamic acid (VAN)
Glutamic Acid [USAN:INN]
Glutamic acid polymer
Glutamic acid, (D)-isomer
Glutamic acid, L- (7CI,8CI)
Glutamic acid, L-, peptides
Glutamicol
Glutamidex
Glutaminate
glutaminic acid
Glutaminic acid
Glutaminic acid (VAN)
Glutaminol
Glutaton
Gulutamine
Gulutamine (USP)
H-Glu-OH
HSCI1_000269
L Glutamate
L Glutamic acid
L-(+)-Glutamate
L-(+)-glutamic acid
L-(+)-Glutamic acid
L-2-Aminoglutaric acid
L-a-Aminoglutarate
L-a-Aminoglutaric acid
L-alpha-Aminoglutarate
L-alpha-Aminoglutaric acid
L-glu
L-Glu
L-glutamate
L-Glutamate
L-Glutamate, aluminum
L-glutamic acid
L-Glutamic acid
L-Glutamic acid (9CI)
L-Glutamic acid (JAN)
L-Glutamic acid hydrochloride
L-Glutamic acid, homopolymer
L-Glutamic acid, homopolymer (9CI)
L-Glutaminate
L-Glutaminic acid
L-Glutaminsaeure
Lopac0_000529
LS-2330
LS-71885
MolPort-001-770-254
NCGC00024502-01
NCGC00024502-02
NCGC00024502-03
NCGC00024502-04
nchembio.186-comp9
nchembio.198-comp6
nchembio.2007.55-comp22
nchembio.266-comp23
nchembio.586-comp22
nchembio816-comp2
NSC 143503
PDSP1_000128
PDSP1_001539
PDSP2_000127
PDSP2_001523
Poly(alpha-L-glutamic acid)
POLYGLUTAMIC ACID
Poly-L-glutamate
Potassium glutamate
Sodium Glutamate (L-glutamic Acid)
Tocris-0218
UNII-3KX376GY7L
W328502_ALDRICH
|
|
33 |
|
Ergocalciferol |
Approved, Nutraceutical |
Phase 3 |
|
50-14-6 |
5280793 |
Synonyms:
(+)-Vitamin D2
(3b,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-Ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,secoergosta-5,7,10(19)-ol
31316-19-5
47768_SUPELCO
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3ah)-indanylidene]ethylidene]-cyclohexanol
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
beta-Ol
bmse000510
BPBio1_000418
BSPBio_000380
BSPBio_001974
buco-D
Buco-D
C05441
C28H44O
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
Calciferols
Calciferolum
Calciferon 2
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
component of Geltabs Vitamin D
Condacaps
Condocaps
Condol
Crtron
Crystallina
D00187
D2, Vitamin
Daral
D-Arthin
Davitamon D
Davitin
DB00153
Decaps
Dee-osterol
Dee-Osterol
Dee-ron
Dee-Ron
Dee-ronal
Dee-Ronal
Dee-roual
Dee-Roual
delta-Arthin
Deltalin
delta-Tracetten
De-rat concentrate
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
D-Tracetten
E5750_SIGMA
EINECS 200-014-9
Ercalciol
ergocalciferol
|
Ergocalciferol
Ergocalciférol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
'Ergosterol irradiated'
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
Haliver
Hi-deratol
Hi-Deratol
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
Metadee
Mina D2
MLS001332467
MLS001332468
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
Novovitamin-D
NSC 62792
NSC62792
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick_554
Prestwick3_000420
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
Shock-ferol
Shock-ferol sterogyl
SMR000857106
Sorex C.R
Sorex C.R.
SPECTRUM1500276
Spectrum5_000666
ST057150
Sterogyl
STOCK1N-53397
Synthetic vitamin D
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
Vigantol
vio D
vio-D
Vio-D
Viostdrol
Viosterol
Viosterol in oil
Viosterol in Oil
Vitamin D 2
vitamin d-2
Vitamin D2
Vitamin- D2
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
Vitamin-?D2
VITAMIN_D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
|
|
34 |
|
Vitamin D3 |
Approved, Nutraceutical |
Phase 3 |
|
67-97-0 |
5280795 6221 |
Synonyms:
()-Vitamin D3
(+)-vitamin D3
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3Β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
47763_SUPELCO
57651-82-8
67-97-0
7-DEHYDROCHOLESTEROL
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
ACTIVATED
Activated 7-dehydrocholesterol
Arachitol
Bio-0845
bmse000507
BPBio1_000460
BSPBio_000418
BSPBio_002408
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
Calciol
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
cholecalciferol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferols
Cholecalciferolum
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
|
CID7067440
CID7251172
CID7251174
CID9821465
Colecalciferol
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Dihydrocholesterol
DivK1c_006276
Duphafral D3 1000
Ebivit
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
FeraCol
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC375571
NSC-375571
Oleovitamin D3
Prestwick_63
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Provitamine
Provitina
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SpecPlus_000180
Spectrum_001163
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
SR-05000001559
SR-05000001559-3
ST057172
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
Vi-de-3-hydrosol
Vigorsan
VITAMIN D
Vitamin D 3
vitamin d-3
Vitamin D3
Vitamin D-3
Vitamin D3 emulsifiable
VITAMIN D3 POWDER
VITAMIN_D3
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
δ-D
|
|
35 |
|
Camostat |
Experimental |
Phase 3 |
|
59721-28-7 |
|
Synonyms:
|
36 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
37 |
|
Serine Proteinase Inhibitors |
|
Phase 3 |
|
|
|
38 |
|
protease inhibitors |
|
Phase 3 |
|
|
|
Synonyms:
|
39 |
|
HIV Protease Inhibitors |
|
Phase 3 |
|
|
|
40 |
|
Trypsin Inhibitors |
|
Phase 3 |
|
|
|
41 |
|
Ergocalciferols |
|
Phase 3 |
|
|
|
42 |
|
Vitamin D2 |
|
Phase 3 |
|
|
|
43 |
|
Nutrients |
|
Phase 3 |
|
|
|
44 |
|
Trace Elements |
|
Phase 3 |
|
|
|
45 |
|
Micronutrients |
|
Phase 3 |
|
|
|
46 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
47 |
|
Antiprotozoal Agents |
|
Phase 3 |
|
|
|
48 |
|
Antiparasitic Agents |
|
Phase 3 |
|
|
|
49 |
|
Antimalarials |
|
Phase 3 |
|
|
|
50 |
|
Serine |
Investigational, Nutraceutical |
Phase 3 |
|
56-45-1 |
5951 |
Synonyms:
(-)-Serine
(2S)-2-amino-3-Hydroxypropanoate
(2S)-2-amino-3-Hydroxypropanoic acid
(S)-(-)-Serine
(S)-2-amino-3-Hydroxypropanoate
(S)-2-amino-3-Hydroxy-propanoate
(S)-2-amino-3-Hydroxypropanoic acid
(S)-2-amino-3-Hydroxy-propanoic acid
(S)-2-Amino-3-hydroxypropanoic acid
(S)-a-amino-b-Hydroxypropionate
(S)-a-amino-b-Hydroxypropionic acid
(S)-alpha-amino-beta-Hydroxypropionate
(S)-alpha-amino-beta-Hydroxypropionic acid
(S)-b-amino-3-Hydroxypropionate
(S)-b-amino-3-Hydroxypropionic acid
(S)-beta-amino-3-Hydroxypropionate
(S)-beta-amino-3-Hydroxypropionic acid
(S)-Serine
(S)-α-amino-β-hydroxypropionate
(S)-α-amino-β-hydroxypropionic acid
2-amino-3-Hydroxypropanoate
2-amino-3-Hydroxypropanoic acid
3-Hydroxy-L-alanine
|
alpha-Amino-beta-hydroxypropionic acid
beta-Hydroxyalanine
beta-Hydroxy-L-alanine
b-Hydroxyalanine
b-Hydroxy-L-alanine
L Serine
L-(-)-Serine
L-2-amino-3-Hydroxypropionate
L-2-amino-3-Hydroxypropionic acid
L-3-Hydroxy-2-aminopropionate
L-3-Hydroxy-2-aminopropionic acid
L-3-Hydroxy-alanine
L-Ser
L-Serin
L-Serine
S
Ser
Serina
Serine
SERINE
Serinum
β-hydroxyalanine
β-hydroxy-L-alanine
|
|
Interventional clinical trials:
(show top 50)
(show all 396)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
CLINICAL MANAGEMENT OF CHILDHOOD INTESTINAL LYMPHOID NODULAR HYPERPLASIA: A RANDOMIZED CONTROLLED CLINICAL TRIAL. |
Unknown status |
NCT01789294 |
Phase 4 |
Mesalamine |
2 |
A Double Blind Placebo Controlled Randomised Trial to Study the Effects of Birch Pollen Specific Immunotherapy (BP-SIT) on the Symptoms of the Oral Allergy Syndrome in Adult Patients |
Unknown status |
NCT01431859 |
Phase 4 |
|
3 |
Phase 4 Study of Effects of Montelukast Treatment on Allergic Inflammation in Children With and Without Food Allergy, Single Centered, Randomised, Double Blind, Placebo Controlled Parallel Group Cross-over Study |
Completed |
NCT01618929 |
Phase 4 |
Montelukast |
4 |
Integrated Approaches to Food Allergen and Allergy Risk Management: iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions |
Completed |
NCT02552537 |
Phase 4 |
Omeprazole;Placebo |
5 |
Basophil Activation Test (BAT) Sensitivity in Child Food Allergy |
Completed |
NCT01966640 |
Phase 4 |
|
6 |
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens |
Completed |
NCT00557284 |
Phase 4 |
Montelukast;Placebo |
7 |
Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers: Does Dose Matter? |
Completed |
NCT03366298 |
Phase 4 |
|
8 |
Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. A Prospective, Randomised, Clinical Trial. |
Completed |
NCT01694108 |
Phase 4 |
|
9 |
A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis (PAR) |
Completed |
NCT01270958 |
Phase 4 |
Avamys aqueous nasal spray 110mcg |
10 |
Effects of an Association of the Two Bifidobacteria Probiotics Bifidobacterium Breve B632 and Bifidobacterium Breve BR03 in Intestinal Bacterial Colonization and in the Prevention and/or Reduction of the Incidence of Colics in Infants |
Completed |
NCT03219931 |
Phase 4 |
Bifidobacterium breve BR03 and Bifidobacterium breve B632;Placebos |
11 |
The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers |
Completed |
NCT02736734 |
Phase 4 |
CRH |
12 |
Can Vitamin D Supplementation in Infants Prevent Food Allergy in the First Year of Life? The VITALITY Trial. |
Recruiting |
NCT02112734 |
Phase 4 |
Vitamin D;placebo |
13 |
Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana). |
Recruiting |
NCT03964051 |
Phase 4 |
Omalizumab Injection |
14 |
Treatment With Omalizumab in Food Allergic Children (TOFAC) |
Not yet recruiting |
NCT04037176 |
Phase 4 |
Omalizumab |
15 |
Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 |
Unknown status |
NCT00298337 |
Phase 2, Phase 3 |
Mixture of probiotic bacteria and prebiotic oligosaccharide |
16 |
Parmigiano-Reggiano Cheese as a Possible Strategy of Immunonutrition Able to Stimulate the Acquisition of Oral Tolerance in Childre With Cow's Milk Allergy |
Unknown status |
NCT02081651 |
Phase 3 |
|
17 |
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE) |
Completed |
NCT03337542 |
Phase 3 |
|
18 |
Effects of GOS/PDX Supplemented Formula in Preventing and Modifying the History of Allergy and Acute Infections in a Population of Infants at Risk of Atopy |
Completed |
NCT02116452 |
Phase 3 |
|
19 |
Development and Field Testing of Ready-to-use-therapeutic Foods Made of Local Ingredients in Bangladesh for the Treatment of Children With Severe Acute Malnutrition |
Completed |
NCT01889329 |
Phase 2, Phase 3 |
|
20 |
Efficacy of a New Hypotonic Oral Rehydration Solution Containing Zinc and Prebiotics in the Treatment of Children With Acute Diarrhea |
Completed |
NCT01025583 |
Phase 2, Phase 3 |
|
21 |
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy (OIT) in Food Allergic Children and Adults (CoFAR-11) |
Recruiting |
NCT03881696 |
Phase 3 |
Omalizumab;Placebo for Omalizumab;Multi-Allergen Oral Immunotherapy;Placebo for Multi-Allergen Oral Immunotherapy |
22 |
THE PEBBLES STUDY: A Randomised Controlled Trial to Prevent Eczema, Food Allergy and Sensitisation Using a Skin Barrier Improvement Strategy |
Recruiting |
NCT03667651 |
Phase 3 |
EpiCeram |
23 |
An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus |
Recruiting |
NCT04355052 |
Phase 3 |
hydroxychloroquine in combination with camostat mesylate;Hydroxychloroquine in combination of Azithromycin |
24 |
Phase III Study of Metabolic Intervention With Glutamate in Coronary Surgery II |
Recruiting |
NCT02592824 |
Phase 3 |
glutamate infusion;saline infusion |
25 |
Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut |
Active, not recruiting |
NCT03013517 |
Phase 3 |
Viaskin Peanut 250µg |
26 |
Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART) |
Active, not recruiting |
NCT00920621 |
Phase 3 |
|
27 |
A Randomised, Controlled Trial to Determine if BCG Immunisation at Birth Reduces Allergy and Infection in Infants |
Active, not recruiting |
NCT01906853 |
Phase 3 |
|
28 |
Efficacite et Innocuite du Tannate de Gelatine Dans le Traitement de la Diarrhee aiguë de l'Enfant. Une Etude Randomisee, Controlee, en Double Aveugle (INDIGO) |
Not yet recruiting |
NCT04065529 |
Phase 3 |
|
29 |
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease. |
Suspended |
NCT04329611 |
Phase 3 |
Hydroxychloroquine |
30 |
Investigation of the Efficacy of the Food Allergy Herbal Formula (FAHF-2TM) in Patients With Food Allergy - Phase II Trial |
Unknown status |
NCT00602160 |
Phase 2 |
FAHF-2 (TM) |
31 |
The Effect of Extrinsic Factors on Food Allergy |
Unknown status |
NCT01429896 |
Phase 2 |
|
32 |
Clinical Desensitization and Tolerance Following Peanut Oral Immunotherapy and Subsequent Allergen Avoidance |
Unknown status |
NCT01750879 |
Phase 1, Phase 2 |
Peanut Flour;Oat Flour |
33 |
Effectiveness and Efficacy of Zinc With Probiotics for the Treatment of Acute Diarrhea in Young Children |
Unknown status |
NCT01140074 |
Phase 2 |
Zinc Sulfate |
34 |
Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients |
Completed |
NCT02643862 |
Phase 1, Phase 2 |
Xolair;Placebo |
35 |
Oral Desensitization to Egg With Subsequent Induction of Sustained Unresponsiveness for Egg-Allergic Children Using Baked Egg or Egg Oral Immunotherapy (OIT) |
Completed |
NCT01846208 |
Phase 2 |
Egg Oral Immunotherapy;Baked Egg |
36 |
Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Children and Adults (DAIT COFAR6) |
Completed |
NCT01904604 |
Phase 2 |
|
37 |
A Phase 2 Study Multi Oral Immunotherapy in Multi Food Allergic Patients to Test Tolerance M-TAX Study |
Completed |
NCT02626611 |
Phase 2 |
Omalizumab;Food Flour Buildup |
38 |
A Phase 2 Study Multi Oral Immunotherapy in Multi Food Allergic Patients to Test Immune Markers After Minimum Maintenance Dose |
Completed |
NCT03181009 |
Phase 2 |
Omalizumab;Food Flour Allergens |
39 |
Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Pilot Study With a Whole Peanut Extract |
Completed |
NCT00580606 |
Phase 1, Phase 2 |
Glycerinated peanut allergenic extract;Placebo for peanut extract (glycerin) |
40 |
Inhibition of Anaphylaxis by Ibrutinib |
Completed |
NCT03149315 |
Phase 2 |
Ibrutinib |
41 |
Oral Desensitization to Egg With Subsequent Induction of Tolerance for Egg-Allergic Children (CoFAR 3) |
Completed |
NCT00461097 |
Phase 2 |
Egg oral immunotherapy;Control Group |
42 |
Effects of Omalizumab on Peanut Allergen Induced Cellular and Clinical Responses in Peanut Allergic Adults |
Completed |
NCT00949078 |
Phase 2 |
omalizumab |
43 |
Oral Immunotherapy for Wheat Allergy |
Completed |
NCT01980992 |
Phase 1, Phase 2 |
Wheat OIT |
44 |
Pilot Study of Omalizumab in Eosinophilic Gastroenteritis |
Completed |
NCT00084097 |
Phase 2 |
Omalizumab |
45 |
Dietary Intervention in Milk Allergy and Tolerance Development |
Completed |
NCT00778258 |
Phase 2 |
|
46 |
FAST-Fish -Food Allergy Specific Treatment for Fish Allergy. |
Completed |
NCT02017626 |
Phase 1, Phase 2 |
|
47 |
A Double-blinded, Placebo-controlled Study of Peanut Sublingual Immunotherapy in Children - DBPC Peanut SLIT |
Completed |
NCT00597727 |
Phase 2 |
Peanut SLIT;Placebo SLIT |
48 |
Mechanisms of Desensitization During Peanut Oral Immunotherapy |
Completed |
NCT01814241 |
Phase 2 |
Open label peanut OIT |
49 |
A Multinational Phase IIb Study to Investigate the Efficacy and Safety of Subcutaneous Immunotherapy With a Modified Fish- Parvalbumin Given in Single Rising and Maintenance Doses to Subjects Allergic to Fish |
Completed |
NCT02382718 |
Phase 2 |
|
50 |
Oral Immunotherapy for Peanut Allergy (2nd Generation PMIT Collaboration With Arkansas Children's) |
Completed |
NCT00597675 |
Phase 2 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|